Affimed NV (LTS:0HL9)
$ 4.27 0.36 (9.21%) Market Cap: 65.48 Mil Enterprise Value: 7.48 Mil PE Ratio: 0 PB Ratio: 1.02 GF Score: 55/100

Affimed NV at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 14, 2021 / 12:30PM GMT
Release Date Price: $71.31 (+1.76%)
Unidentified Analyst

Hello, everyone, and welcome back to the conference. I'm [Nater Sarabi]. I'm a member of JPMorgan's healthcare investment banking team. On behalf of JPMorgan, it's my pleasure to introduce Dr. Adi Hoess, the CEO of Affimed; and Alex Fudukidis, Affimed's Head of Investor Relations.

We'll try to reserve a few minutes at the end for Q&A. (Operator Instructions)

I'll now turn it over to Adi and Alex to tell you more about Affimed. Thank you.

Adi Hoess
Affimed N.V. - CEO, MD & Member of Management Board

Thank you, Nater, for the introduction, and welcome, everybody, to the Affimed presentation. And introducing to you the ways how we believe that we can advance immuno-oncology and our idea, in particular, is to activate the innate immune system, specifically natural killer cells and macrophages.

I'll move to Slide 3, that in the center of our thinking indeed is the patient. And we do indeed see lots of patients that are receiving treatments that have great benefit to them. But we're seeing probably many more

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot